Matches in SemOpenAlex for { <https://semopenalex.org/work/W2279491468> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W2279491468 endingPage "TPS248" @default.
- W2279491468 startingPage "TPS248" @default.
- W2279491468 abstract "TPS248 Background: Biochemical recurrence without evidence of PC on standard CT/MRI and bone scans after local therapy is common. Salvage radiotherapy affords a cure to a proportion of pts with biochemical relapse, but most suffer disease progression because of micrometastatic PC outside of the radiation field. J591 is a monoclonal antibody that targets the extracellular domain of prostate specific membrane antigen (PSMA). A phase II trial of single-dose 177Lu-J591 radioimmunotherapy (RIT) in pts with progressive, metastatic castration-resistant prostate cancer (CRPC) demonstrated excellent targeting of metastatic sites, efficacy, and acceptable toxicity (Tagawa et al, ASCO 2008). In general, RIT appears to have its greatest impact in the setting of minimal disease (Kaminski NEJM 2005; Leonard JCO2005; Press JCO 2006) and the beta emission of 177Lu is best suited for lesions 1-3 mm in diameter (O'Donoghue J Nuc Med 1995) (i.e. micrometastatic disease). Methods: Men with high-risk CRPC (PSA doubling time < 8 months and/or PSA > 20 [Smith JCO 2005]) and no evidence of disease on CT/MRI and bone scans are randomized in a 2:1 fashion to receive double-blinded 177Lu-J951 vs 111In-J591 (control) and will undergo planar gamma camera imaging with SPECT following infusion. All pts receive ketoconazole plus hydrocortisone. The primary endpoint of the study is 18-month metastasis-free survival. 140 pts will be treated to allow 80% power with a 2-sided alpha of 5% to detect a 25% absolute difference (50% vs. 75% metastasis free) in radiographically apparent metastasis at 18 months (with interim analysis after 50% of pts have at least 12 months follow- up). Secondary/exploratory endpoints include evaluation of radiolabeled J591 imaging to detect sites of metastases not apparent on standard CT/MRI and bone scan, validation of adrenal androgen levels as biomarkers for ketoconazole (Ryan Clin Cancer Res 2007), analysis of circulating tumor cells for PSMA expression and to predict the appearance of radiographic metastases, and exploration of plasma markers of hemostasis, fibrinolysis, and angiogenesis as biomarkers. No significant financial relationships to disclose." @default.
- W2279491468 created "2016-06-24" @default.
- W2279491468 creator A5002621242 @default.
- W2279491468 creator A5007663088 @default.
- W2279491468 creator A5020127308 @default.
- W2279491468 creator A5024592292 @default.
- W2279491468 creator A5028538472 @default.
- W2279491468 creator A5036798940 @default.
- W2279491468 creator A5047882814 @default.
- W2279491468 creator A5051796644 @default.
- W2279491468 creator A5065880705 @default.
- W2279491468 creator A5082058065 @default.
- W2279491468 date "2010-05-20" @default.
- W2279491468 modified "2023-09-28" @default.
- W2279491468 title "A randomized phase II trial of 177lu radiolabeled monoclonal antibody J591 (177Lu-J591) and ketoconazole in patients (pts) with high-risk castrate biochemically relapsed prostate cancer (PC) after local therapy." @default.
- W2279491468 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.tps248" @default.
- W2279491468 hasPublicationYear "2010" @default.
- W2279491468 type Work @default.
- W2279491468 sameAs 2279491468 @default.
- W2279491468 citedByCount "1" @default.
- W2279491468 countsByYear W22794914682017 @default.
- W2279491468 crossrefType "journal-article" @default.
- W2279491468 hasAuthorship W2279491468A5002621242 @default.
- W2279491468 hasAuthorship W2279491468A5007663088 @default.
- W2279491468 hasAuthorship W2279491468A5020127308 @default.
- W2279491468 hasAuthorship W2279491468A5024592292 @default.
- W2279491468 hasAuthorship W2279491468A5028538472 @default.
- W2279491468 hasAuthorship W2279491468A5036798940 @default.
- W2279491468 hasAuthorship W2279491468A5047882814 @default.
- W2279491468 hasAuthorship W2279491468A5051796644 @default.
- W2279491468 hasAuthorship W2279491468A5065880705 @default.
- W2279491468 hasAuthorship W2279491468A5082058065 @default.
- W2279491468 hasConcept C121608353 @default.
- W2279491468 hasConcept C126322002 @default.
- W2279491468 hasConcept C126894567 @default.
- W2279491468 hasConcept C143998085 @default.
- W2279491468 hasConcept C159654299 @default.
- W2279491468 hasConcept C168563851 @default.
- W2279491468 hasConcept C203014093 @default.
- W2279491468 hasConcept C203092338 @default.
- W2279491468 hasConcept C2776146153 @default.
- W2279491468 hasConcept C2776694085 @default.
- W2279491468 hasConcept C2778822529 @default.
- W2279491468 hasConcept C2779013556 @default.
- W2279491468 hasConcept C2780192828 @default.
- W2279491468 hasConcept C2989005 @default.
- W2279491468 hasConcept C509974204 @default.
- W2279491468 hasConcept C542903549 @default.
- W2279491468 hasConcept C71924100 @default.
- W2279491468 hasConceptScore W2279491468C121608353 @default.
- W2279491468 hasConceptScore W2279491468C126322002 @default.
- W2279491468 hasConceptScore W2279491468C126894567 @default.
- W2279491468 hasConceptScore W2279491468C143998085 @default.
- W2279491468 hasConceptScore W2279491468C159654299 @default.
- W2279491468 hasConceptScore W2279491468C168563851 @default.
- W2279491468 hasConceptScore W2279491468C203014093 @default.
- W2279491468 hasConceptScore W2279491468C203092338 @default.
- W2279491468 hasConceptScore W2279491468C2776146153 @default.
- W2279491468 hasConceptScore W2279491468C2776694085 @default.
- W2279491468 hasConceptScore W2279491468C2778822529 @default.
- W2279491468 hasConceptScore W2279491468C2779013556 @default.
- W2279491468 hasConceptScore W2279491468C2780192828 @default.
- W2279491468 hasConceptScore W2279491468C2989005 @default.
- W2279491468 hasConceptScore W2279491468C509974204 @default.
- W2279491468 hasConceptScore W2279491468C542903549 @default.
- W2279491468 hasConceptScore W2279491468C71924100 @default.
- W2279491468 hasIssue "15_suppl" @default.
- W2279491468 hasLocation W22794914681 @default.
- W2279491468 hasOpenAccess W2279491468 @default.
- W2279491468 hasPrimaryLocation W22794914681 @default.
- W2279491468 hasRelatedWork W2021868094 @default.
- W2279491468 hasRelatedWork W2088950395 @default.
- W2279491468 hasRelatedWork W2138369028 @default.
- W2279491468 hasRelatedWork W2156659229 @default.
- W2279491468 hasRelatedWork W2417374591 @default.
- W2279491468 hasRelatedWork W248126025 @default.
- W2279491468 hasRelatedWork W2808552915 @default.
- W2279491468 hasRelatedWork W3171492215 @default.
- W2279491468 hasRelatedWork W3212782699 @default.
- W2279491468 hasRelatedWork W4225123234 @default.
- W2279491468 hasVolume "28" @default.
- W2279491468 isParatext "false" @default.
- W2279491468 isRetracted "false" @default.
- W2279491468 magId "2279491468" @default.
- W2279491468 workType "article" @default.